|
史世杰.吸入一氧化氮在急性呼吸窘迫综合征治疗中的作用及挑战：从生理机制到临床应用的综述[J].内科急危重症杂志,2025,31(5):458-463
|
| DOI：10.11768/nkjwzzzz20250513 |
| 中文关键词: 急性呼吸窘迫综合征 吸入一氧化氮 体外膜肺氧合 |
| 英文关键词: |
| 基金项目:湖北省教育厅科研项目(B2020103) ; 湖北省卫健委科研项目( WJ2021F039) |
|
| 摘要点击次数: 18 |
| 全文下载次数: 24 |
| 中文摘要: |
| 摘要 急性呼吸窘迫综合征（ARDS）是一种临床表现为严重低氧血症的重症肺部疾病，一氧化氮（NO）作为选择性肺血管扩张剂逐渐应用在ARDS的治疗中，如纠正顽固性低氧血症及为体外膜肺氧合（ECMO）治疗提供更多时间或减少其使用，但吸入一氧化氮（iNO）在降低成人ARDS患者的死亡率或住院时间上并未达到明显效果，并且合并多种潜在并发症。ARDS是一种复杂且危重的疾病，其治疗需要综合多种策略和手段，NO无疑为ARDS的治疗带来了新的可能性，但如何在临床实践中最大限度地发挥其优势，同时避免其潜在的风险，是目前临床和基础研究者们持续努力的方向。 |
| 英文摘要: |
| Abstract Acute respiratory distress syndrome （ARDS) is a severe pulmonary disease characterized by severe hypoxemia. Nitric oxide (NO) as a selective pulmonary vasodilator, has been increasingly applied in the treatment of ARDS, such as correcting refractory hypoxemia and providing more time for extracorporeal membrane oxygenation therapy or reducing its use. However, inhaled NO has not achieved significant effects in reducing the mortality rate or hospital stay of adult ARDS patients, and is associated with a variety of potential complications. ARDS is a complex and critical disease, and its treatment requires a combination of multiple strategies and approaches. Undoubtedly, NO has brought new possibilities for the treatment of ARDS, but how to maximize its advantages in clinical practice while avoiding its potential risks remains a continuous focus of efforts for current clinical and basic researchers. |
|
